HER2 amplification was identified from one patient, consistent with previous reports that HER2 amplification conferred resistance to anti-HER2 targeted therapy in HER2-mutant NSCLC (6, 31). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.